Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide Injection vs Ozempic in Type 2 Diabetes with Poor Glycemic Control on Metformin
NCT06339086Phase 3Not yet recruiting
- Sponsor
- Chengdu Brilliant Pharmaceutical Co., Ltd.
- Start
- Apr 2024
- Primary completion
- Aug 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Chengdu Brilliant Pharmaceutical Co., Ltd.. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06339086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06339086.